IRIS
MARCHICA, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.622
EU - Europa 1.409
AS - Asia 850
SA - Sud America 104
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 4.020
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.587
CN - Cina 372
SG - Singapore 335
SE - Svezia 292
IE - Irlanda 289
IT - Italia 288
DE - Germania 126
BR - Brasile 89
TR - Turchia 69
NL - Olanda 68
FR - Francia 65
FI - Finlandia 63
AT - Austria 61
RU - Federazione Russa 33
CA - Canada 28
GB - Regno Unito 24
CZ - Repubblica Ceca 21
RO - Romania 21
BE - Belgio 17
CI - Costa d'Avorio 16
IN - India 16
BD - Bangladesh 9
UA - Ucraina 8
HK - Hong Kong 7
ID - Indonesia 7
EU - Europa 6
LT - Lituania 6
ES - Italia 5
BG - Bulgaria 4
IL - Israele 4
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
IQ - Iraq 3
IR - Iran 3
KH - Cambogia 3
LU - Lussemburgo 3
MX - Messico 3
SC - Seychelles 3
AR - Argentina 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
DK - Danimarca 2
EC - Ecuador 2
KE - Kenya 2
LV - Lettonia 2
MA - Marocco 2
MD - Moldavia 2
NG - Nigeria 2
PE - Perù 2
PH - Filippine 2
PL - Polonia 2
PY - Paraguay 2
QA - Qatar 2
SM - San Marino 2
UZ - Uzbekistan 2
VE - Venezuela 2
ZA - Sudafrica 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
GT - Guatemala 1
JO - Giordania 1
JP - Giappone 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
VN - Vietnam 1
Totale 4.020
Salva come PNG Salva come JPEG
Città #
Chandler 333
Dublin 286
Singapore 195
Santa Clara 175
Parma 132
Ashburn 124
Ann Arbor 93
Shanghai 90
Boardman 71
Dearborn 67
New York 57
Vienna 56
Izmir 54
Nanjing 51
Beijing 46
Princeton 45
Marseille 37
Helsinki 28
Wilmington 27
Los Angeles 26
Bremen 23
Munich 23
Shenyang 23
Moscow 22
Brno 18
Toronto 18
Brussels 17
Abidjan 16
Milan 15
San Mateo 15
Hebei 14
Kunming 14
Council Bluffs 13
Düsseldorf 13
Jinan 13
Nanchang 13
Kocaeli 12
Focsani 10
Modena 10
Redmond 10
Bologna 8
Changsha 8
Fairfield 8
Houston 8
Jiaxing 8
Woodbridge 8
Guangzhou 7
Hefei 7
Jakarta 7
London 7
Norwalk 7
Dallas 6
Hong Kong 6
Nuremberg 6
Ottawa 6
Pune 6
Savignano sul Rubicone 6
São Paulo 6
Tianjin 6
Washington 6
Zhengzhou 6
Des Moines 5
Frankfurt am Main 5
Hangzhou 5
Jacksonville 5
Madrid 5
Palermo 5
Rho 5
Rome 5
Seattle 5
Rio Saliceto 4
Romainville 4
Sofia 4
Torino 4
Ahmedabad 3
Amsterdam 3
Cesena 3
Dubai 3
Fremont 3
Gorgonzola 3
Lauterbourg 3
Lviv 3
Nürnberg 3
Phnom Penh 3
Redwood City 3
Reggio Emilia 3
Rio de Janeiro 3
San Giuliano Milanese 3
St Louis 3
Stockholm 3
Tel Aviv 3
Wuhan 3
Arcevia 2
Belo Horizonte 2
Borås 2
Campinas 2
Cape Town 2
Cento 2
Chengdu 2
Chisinau 2
Totale 2.579
Salva come PNG Salva come JPEG
Nome #
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 122
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 120
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 120
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 107
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 105
Novel targets for the treatment of relapsing multiple myeloma 105
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 104
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 101
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 96
Oncolytic virotherapy and microenvironment in multiple myeloma 95
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 95
A simplified sars-cov-2 pseudovirus neutralization assay 95
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 93
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 93
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 92
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 92
Possible targets to treat myeloma-related osteoclastogenesis 91
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 90
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 90
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 88
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 88
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 87
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 87
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 86
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 84
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 83
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 82
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 79
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 79
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 78
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 77
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 77
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 76
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 76
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 74
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 72
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 72
Role of Galectins in Multiple Myeloma. 65
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 63
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 63
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 61
The impact of CD56 expression in smoldering myeloma patients on early progression 60
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 60
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 60
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 56
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 50
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 49
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 47
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 47
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 39
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 35
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 34
Totale 4.140
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.023
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.023
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202052 0 0 0 0 0 0 0 0 0 36 10 6
2020/2021250 30 4 7 7 40 8 15 22 44 28 16 29
2021/2022296 6 10 10 23 6 7 43 35 26 15 19 96
2022/20231.244 129 141 92 100 102 137 50 81 340 14 45 13
2023/2024540 22 43 14 14 37 160 49 11 24 43 26 97
2024/20251.121 27 60 84 140 162 142 106 87 194 119 0 0
Totale 4.140